Skip to content
Open access

Characterization of demographic, clinical and neuroimaging profiles of non-amnestic Alzheimer's disease phenotypes in a tertiary cognitive neurology outpatient clinic

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Alzheimer's disease (AD) primarily presents with amnestic decline, but atypical variants — logopenic variant of Primary Progressive Aphasia (lvPPA), Posterior Cortical Atrophy (PCA), dysexecutive/behavioral variant (bvAD) and Corticobasal Syndrome (CBS) — account for up to 15% of early-onset cases and pose significant diagnostic challenges. Characterizing these trajectories is essential for early diagnosis and accurate prognosis. Objective: To characterize and compare demographic, clinical, neuropsychological, neuroimaging and genetic profiles between typical AD and atypical variants, validating topographic signatures and clinical progression rates. Methods: Observational cohort study including 87 patients from a tertiary Cognitive Neurology center: 62 typical AD and 25 atypical variants (lvPPA=7, PCA=7, bvAD=6, CBS=5). Assessment included Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Brief Cognitive Screening Battery (BCSB), Pfeffer Functional Activities Questionnaire (FAQ) and Katz Index; neurological signs; magnetic resonance imaging (MRI) (67/87) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) (50/87). Biological diagnosis was established by cerebrospinal fluid (CSF) biomarkers, amyloid-PET or genetic mutation in 19 cases. Results: Atypical variants showed earlier onset (PCA/CBS 53.0 vs. typical AD 63.5 years), greater cognitive impairment (MMSE 12.0 vs. 18.0; p=0.003) and functional decline (Katz 4.0 vs. 6.0; p=0.01). Delayed recall preserved in atypical (bvAD=6.0; CBS=4.0) vs. typical AD (2.0), validating non-amnestic profile. Typical AD associated with prior depression (38.7%; p=0.04); PCA with family history (85.7%). In progression, bvAD exhibited -5.47 points/year on MMSE, 4x higher than typical AD (-1.33); PCA (-1.74), lvPPA (-1.60) and CBS (-1.50) with intermediate rates. Phenotypic validation: diagnosis-initial symptom association (p<0.0001); PCA with Balint/Gerstmann syndromes (p<0.001); lvPPA with aphasia (p=0.0001); CBS with parkinsonism (40%) and myoclonus (20%). High neuroimaging concordance: PCA/bvAD/CBS 100%, lvPPA 85.7%, typical AD 71%. FDG-PET superior to MRI: in bvAD, frontal hypometabolism 100% vs. 0% atrophy, confirming metabolic dysfunction precedes structural changes. Small vessel disease higher in atypical (p=0.03), suggesting cerebral amyloid angiopathy contribution. No MMSE difference between biomarker-confirmed (17.0) and probable (15.5; p=0.63), validating diagnostic accuracy. PSEN1/APP mutations (n=6): 12.5-year anticipation (51.0 vs. 63.5; p=0.0002). Conclusion: Atypical AD variants present earlier onset, greater baseline severity and aggressive progression, particularly bvAD with 4x faster decline. FDG-PET outperformed MRI, detecting metabolic dysfunction before structural atrophy. Small vessel disease suggests amyloid angiopathy contribution. PSEN1/APP mutations caused 12.5-year anticipation. These findings reinforce the need for a multimodal approach integrating clinical, neuroimaging and biomarkers.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.